NEW ORLEANS, Oct. 25, 2022 (GLOBE NEWSWIRE) — ClaimsFiler, a FREE shareholder information service, is reminding investors they have until November 28, 2022 Lead plaintiff’s motions in a securities class action against Centessa Pharmaceuticals plc CNTAif they purchased or otherwise acquired the Company’s securities and/or purchased the Company’s American Depositary Shares (“ADSs”) between May 28, 2021 and June 1, 2022 inclusive (the “Collection Period”), as disclosed by the Company or otherwise acquired May 2021 Initial Public Offering (the “IPO”). This lawsuit is pending in the United States District Court for the Southern District of New York.

get help

Centessa investors should visit us at https://claimsfiler.com/cases/nasdaq-cnta/ or call toll free (844) 367-9658. Kahn Swick & Foti, LLC attorneys are available to discuss your legal options.

About the lawsuit

Centessa and certain of its officers are alleged to have failed to disclose material information during the Class Period and/or in the registration statement and prospectus issued in connection with the IPO, in violation of federal securities laws.

The alleged false and misleading statements and omissions include, but are not limited to: (i) lixivaptan, the Company’s drug product, was less safe than the Company had made it out to be; (ii) the company has overstated the clinical efficacy and commercial viability of lixivaptan; (iii) ZF874, another of the company’s medicines, was less safe than the company had represented; (iv) the company has overstated the clinical efficacy and commercial viability of ZF874 while downplaying the drug’s safety issues; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

The case is Fernandes v. Centessa Pharmaceuticals Plc, et al., No. 22-cv-07030.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as an information resource to help individual investors claim their share of billions of…